CSIMarket



Best Performing Stocks In Healthcare Sector During This Current Quarter Q3 Of 2024



 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 
 

Shares improved by 12.25% on average, in Healthcare Sector during this current quarter q3 of 2024.

Here are the best performing stocks in Healthcare Sector.




GH

$32.105

$15.4350 92.59%
This Quarter Q3 of 2024


GH

$32.105

$15.4350 92.59%



Guardant Health Inc

Guardant Health Inc stock went up 92.59% during this current quarter q3 of 2024.


Guardant Health Inc*s business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,907.564 mill. $ 603.725 mill. $ -460.901 mill. 122 mill. - Y/Y 30.90 %
Market Cap. Revenues TTM Net Income TTM

$ 3,907.564 mill.


$ 603.725 mill.


$ -460.901 mill.

Employees Shares Outstanding P/E

1,100


122 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 30.90 %


MRQ Y/Y - %



THC

$137.8084

$46.7284 51.30%
This Quarter Q3 of 2024


THC

$137.8084

$46.7284 51.30%



Tenet Healthcare Corp

Tenet Healthcare Corp shares improved 51.30% during this current quarter q3 of 2024.


Tenet Healthcare Corp operates as a healthcare services company that primarily focuses on managing and providing healthcare facilities, including hospitals, outpatient centers, and physician practices. Their business model revolves around delivering high-quality patient care, optimizing operational efficiency, and maintaining strong physician relationships. They aim to provide comprehensive healthcare services to diverse communities, utilizing advanced medical technology and a multispecialty approach to address the healthcare needs of individuals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13,863.249 mill. $ 20,895.000 mill. $ 3,349.000 mill. 101 mill. 5.32 Y/Y 6.91 %
Market Cap. Revenues TTM Net Income TTM

$ 13,863.249 mill.


$ 20,895.000 mill.


$ 3,349.000 mill.

Employees Shares Outstanding P/E

108,000


101 mill.


5.32

Revenue Growth Income Growth

MRQ Y/Y 6.91 %


MRQ Y/Y 688.51 %



KEQU

$53.4748

$18.0648 51.02%
This Quarter Q3 of 2024


KEQU

$53.4748

$18.0648 51.02%



Kewaunee Scientific Corporation

Kewaunee Scientific Corporation stock increased 51.02% during this current quarter q3 of 2024.


Kewaunee Scientific Corp operates as a global provider of laboratory furniture, fume hoods, and related equipment. Their business model revolves around designing, manufacturing, and installing these products for various industries including pharmaceutical, chemical, and healthcare. They aim to provide customized laboratory solutions while focusing on quality, safety, and compliance with industry standards.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 157.181 mill. $ 203.051 mill. $ 19.057 mill. 3 mill. 8.51 Y/Y 8.62 %
Market Cap. Revenues TTM Net Income TTM

$ 157.181 mill.


$ 203.051 mill.


$ 19.057 mill.

Employees Shares Outstanding P/E

1,357


3 mill.


8.51

Revenue Growth Income Growth

MRQ Y/Y 8.62 %


MRQ Y/Y 921.85 %



ARGX

$460.295

$101.8850 28.43%
This Quarter Q3 of 2024


ARGX

$460.295

$101.8850 28.43%



Argenx se

Argenx Se stock went up 28.43% during this current quarter q3 of 2024.


Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 26,314.721 mill. $ 2,494.910 mill. $ -295.053 mill. 57 mill. - Y/Y 191.46 %
Market Cap. Revenues TTM Net Income TTM

$ 26,314.721 mill.


$ 2,494.910 mill.


$ -295.053 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 191.46 %


MRQ Y/Y - %



AMGN

$336.3307

$73.5807 28.00%
This Quarter Q3 of 2024


AMGN

$336.3307

$73.5807 28.00%



Amgen Inc

Amgen Inc shares increased 28.00% during this current quarter q3 of 2024.


Amgen Inc*s business model is centered around developing, manufacturing, and commercializing innovative biotechnology products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 180,273.255 mill. $ 29,532.000 mill. $ 3,763.000 mill. 536 mill. 48.03 Y/Y 21.98 %
Market Cap. Revenues TTM Net Income TTM

$ 180,273.255 mill.


$ 29,532.000 mill.


$ 3,763.000 mill.

Employees Shares Outstanding P/E

24,200


536 mill.


48.03

Revenue Growth Income Growth

MRQ Y/Y 21.98 %


MRQ Y/Y - %



ISRG

$458.3754

$85.7454 23.01%
This Quarter Q3 of 2024


ISRG

$458.3754

$85.7454 23.01%



Intuitive Surgical Inc

Intuitive Surgical Inc shares improved 23.01% during this current quarter q3 of 2024.


Intuitive Surgical Inc*s business model revolves around providing robotic surgical systems, instruments, and accessories to hospitals and healthcare facilities. Their flagship product, the da Vinci Surgical System, enables surgeons to perform minimally invasive surgeries with enhanced precision and control. The company generates revenue through the sale of these systems and associated instruments, as well as through training, services, and maintenance provided to its customers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 165,473.519 mill. $ 7,571.500 mill. $ 2,109.400 mill. 361 mill. 78.57 Y/Y 14.45 %
Market Cap. Revenues TTM Net Income TTM

$ 165,473.519 mill.


$ 7,571.500 mill.


$ 2,109.400 mill.

Employees Shares Outstanding P/E

9,793


361 mill.


78.57

Revenue Growth Income Growth

MRQ Y/Y 14.45 %


MRQ Y/Y 24.77 %



BIIB

$226.19

$35.6700 18.72%
This Quarter Q3 of 2024


BIIB

$226.19

$35.6700 18.72%



Biogen Inc

Biogen Inc shares improved 18.72% during this current quarter q3 of 2024.


Biogen Inc*s business model revolves around researching, developing, and commercializing therapies for neurological and neurodegenerative diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 33,001.121 mill. $ 9,663.100 mill. $ 1,167.300 mill. 146 mill. 28.27 Y/Y -7.00 %
Market Cap. Revenues TTM Net Income TTM

$ 33,001.121 mill.


$ 9,663.100 mill.


$ 1,167.300 mill.

Employees Shares Outstanding P/E

9,610


146 mill.


28.27

Revenue Growth Income Growth

MRQ Y/Y -7.00 %


MRQ Y/Y 1.50 %



OGN

$21.105

$3.2450 18.17%
This Quarter Q3 of 2024


OGN

$21.105

$3.2450 18.17%



Organon and Co

Organon And Co shares increased 18.17% during this current quarter q3 of 2024.


Organon and Co*s business model revolves around developing and manufacturing pharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,452.730 mill. $ 6,347.000 mill. $ 1,047.000 mill. 258 mill. 5.18 Y/Y 5.46 %
Market Cap. Revenues TTM Net Income TTM

$ 5,452.730 mill.


$ 6,347.000 mill.


$ 1,047.000 mill.

Employees Shares Outstanding P/E

9,300


258 mill.


5.18

Revenue Growth Income Growth

MRQ Y/Y 5.46 %


MRQ Y/Y 13.56 %



PODD

$194.36

$29.6300 17.99%
This Quarter Q3 of 2024


PODD

$194.36

$29.6300 17.99%



Insulet Corporation

Insulet Corporation shares went up 17.99% during this current quarter q3 of 2024.


Insulet Corporation operates under a business model where they design, develop, and market innovative tubeless insulin delivery systems for people with diabetes. Their main product, the Omnipod System, is a wearable device that provides continuous insulin delivery without the need for traditional insulin pumps and tubing. This unique business model focuses on improving the quality of life for individuals with diabetes by offering a convenient and user-friendly insulin management solution.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 14,332.301 mill. $ 1,780.700 mill. $ 234.000 mill. 74 mill. 63.16 Y/Y 23.35 %
Market Cap. Revenues TTM Net Income TTM

$ 14,332.301 mill.


$ 1,780.700 mill.


$ 234.000 mill.

Employees Shares Outstanding P/E

3,500


74 mill.


63.16

Revenue Growth Income Growth

MRQ Y/Y 23.35 %


MRQ Y/Y 116.39 %



BSX

$78.665

$11.2450 16.68%
This Quarter Q3 of 2024


BSX

$78.665

$11.2450 16.68%



Boston Scientific Corporation

Boston Scientific Corporation stock went up 16.68% during this current quarter q3 of 2024.


Boston Scientific Corporation*s business model revolves around designing, developing, and manufacturing a wide range of medical devices that are used in various medical specialties. The company focuses on creating innovative products that address unmet medical needs and improve patient outcomes. They sell these devices to healthcare professionals and hospitals worldwide, leveraging their strong sales and distribution networks. Additionally, Boston Scientific actively invests in research and development to continuously bring new technologies and solutions to the market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 116,557.931 mill. $ 14,709.000 mill. $ 1,771.000 mill. 1,482 mill. 68.23 Y/Y 13.81 %
Market Cap. Revenues TTM Net Income TTM

$ 116,557.931 mill.


$ 14,709.000 mill.


$ 1,771.000 mill.

Employees Shares Outstanding P/E

41,000


1,482 mill.


68.23

Revenue Growth Income Growth

MRQ Y/Y 13.81 %


MRQ Y/Y 57.01 %



PFE

$29.585

$4.1950 16.52%
This Quarter Q3 of 2024


PFE

$29.585

$4.1950 16.52%



Pfizer Inc

Pfizer Inc shares went up 16.52% during this current quarter q3 of 2024.


Pfizer Inc operates as a global pharmaceutical company, focused on discovering, developing, manufacturing, and marketing innovative medicines. Its business model revolves around investing in research and development to create a diverse portfolio of therapies across various therapeutic areas. Leveraging its scale, Pfizer aims to commercialize these products globally and drive growth through strategic alliances and collaborations with other industry players.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 168,545.745 mill. $ 55,093.000 mill. $ -275.000 mill. 5,697 mill. - Y/Y -18.61 %
Market Cap. Revenues TTM Net Income TTM

$ 168,545.745 mill.


$ 55,093.000 mill.


$ -275.000 mill.

Employees Shares Outstanding P/E

79,000


5,697 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -18.61 %


MRQ Y/Y -43.79 %



LLY

$868.335

$122.3850 16.41%
This Quarter Q3 of 2024


LLY

$868.335

$122.3850 16.41%



Eli Lilly And Company

Eli Lilly And Company shares increased 16.41% during this current quarter q3 of 2024.


Eli Lilly and Company operates as a pharmaceutical company, primarily focused on researching, developing, manufacturing, and marketing prescription drugs across various therapeutic areas.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 784,801.173 mill. $ 35,932.100 mill. $ 6,138.400 mill. 904 mill. 127.81 Y/Y 25.98 %
Market Cap. Revenues TTM Net Income TTM

$ 784,801.173 mill.


$ 35,932.100 mill.


$ 6,138.400 mill.

Employees Shares Outstanding P/E

35,000


904 mill.


127.81

Revenue Growth Income Growth

MRQ Y/Y 25.98 %


MRQ Y/Y 66.77 %



DGX

$146.1

$20.1900 16.04%
This Quarter Q3 of 2024


DGX

$146.1

$20.1900 16.04%



Quest Diagnostics Inc

Quest Diagnostics Inc shares went up 16.04% during this current quarter q3 of 2024.


Quest Diagnostics Inc operates as a provider of clinical laboratory and diagnostic information services, serving patients, physicians, hospitals, and pharmaceutical companies. The company generates revenue by offering a range of diagnostic testing services, including laboratory analysis, test development, and specialized diagnostics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 16,363.200 mill. $ 9,287.000 mill. $ 899.000 mill. 112 mill. 19.71 Y/Y 1.50 %
Market Cap. Revenues TTM Net Income TTM

$ 16,363.200 mill.


$ 9,287.000 mill.


$ 899.000 mill.

Employees Shares Outstanding P/E

49,000


112 mill.


19.71

Revenue Growth Income Growth

MRQ Y/Y 1.50 %


MRQ Y/Y -4.15 %



MTD

$1377.685

$185.1250 15.52%
This Quarter Q3 of 2024


MTD

$1377.685

$185.1250 15.52%



Mettler Toledo International Inc

Mettler Toledo International Inc shares increased 15.52% during this current quarter q3 of 2024.


Mettler Toledo International Inc*s business model revolves around manufacturing and selling precision instruments and solutions for weighing, measuring, and analyzing various materials and substances.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 29,679.899 mill. $ 3,785.520 mill. $ 777.861 mill. 22 mill. 38.59 Y/Y -0.30 %
Market Cap. Revenues TTM Net Income TTM

$ 29,679.899 mill.


$ 3,785.520 mill.


$ 777.861 mill.

Employees Shares Outstanding P/E

17,800


22 mill.


38.59

Revenue Growth Income Growth

MRQ Y/Y -0.30 %


MRQ Y/Y -5.79 %



MMM

$104.54

$13.0600 14.28%
This Quarter Q3 of 2024


MMM

$104.54

$13.0600 14.28%



3m Company

3m Company shares increased 14.28% during this current quarter q3 of 2024.


3M Company is a diversified technology company that operates through various business segments. It focuses on innovation and develops a wide range of products across industries such as healthcare, transportation, consumer goods, and electronics. Its business model involves creating innovative solutions, leveraging its vast portfolio of patents, and maintaining strong relationships with customers and suppliers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 58,113.786 mill. $ 32,653.000 mill. $ -7,027.000 mill. 556 mill. - Y/Y -0.35 %
Market Cap. Revenues TTM Net Income TTM

$ 58,113.786 mill.


$ 32,653.000 mill.


$ -7,027.000 mill.

Employees Shares Outstanding P/E

95,000


556 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -0.35 %


MRQ Y/Y -4.89 %



DVA

$141.555

$15.4450 12.25%
This Quarter Q3 of 2024


DVA

$141.555

$15.4450 12.25%



Davita Inc

Davita Inc shares improved 12.25% during this current quarter q3 of 2024.


Davita Inc operates a network of dialysis centers worldwide, providing kidney care and related services to patients with chronic kidney disease. The company primarily generates revenue through reimbursements from healthcare payors and government programs for the dialysis treatments it offers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 12,817.381 mill. $ 12,338.003 mill. $ 1,092.290 mill. 91 mill. 16.10 Y/Y 6.89 %
Market Cap. Revenues TTM Net Income TTM

$ 12,817.381 mill.


$ 12,338.003 mill.


$ 1,092.290 mill.

Employees Shares Outstanding P/E

69,000


91 mill.


16.10

Revenue Growth Income Growth

MRQ Y/Y 6.89 %


MRQ Y/Y 79.28 %



RVTY

$110.27

$10.8900 10.96%
This Quarter Q3 of 2024


RVTY

$110.27

$10.8900 10.96%



Revvity Inc

Revvity Inc shares increased 10.96% during this current quarter q3 of 2024.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13,622.535 mill. $ 2,170.922 mill. $ 539.895 mill. 124 mill. 25.22 Y/Y -8.69 %
Market Cap. Revenues TTM Net Income TTM

$ 13,622.535 mill.


$ 2,170.922 mill.


$ 539.895 mill.

Employees Shares Outstanding P/E

-


124 mill.


25.22

Revenue Growth Income Growth

MRQ Y/Y -8.69 %


MRQ Y/Y -69.52 %



GILD

$71.85

$5.6900 8.60%
This Quarter Q3 of 2024


GILD

$71.85

$5.6900 8.60%



Gilead Sciences Inc

Gilead Sciences Inc shares went up 8.60% during this current quarter q3 of 2024.


Gilead Sciences Inc*s business model revolves around researching, developing, and commercializing innovative medicines in various therapeutic areas, with a primary focus on antiviral drugs. They aim to address unmet medical needs and improve the lives of patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 89,596.950 mill. $ 27,450.000 mill. $ 458.000 mill. 1,247 mill. 198.39 Y/Y 5.26 %
Market Cap. Revenues TTM Net Income TTM

$ 89,596.950 mill.


$ 27,450.000 mill.


$ 458.000 mill.

Employees Shares Outstanding P/E

14,400


1,247 mill.


198.39

Revenue Growth Income Growth

MRQ Y/Y 5.26 %


MRQ Y/Y - %



TFX

$222.14

$14.7600 7.12%
This Quarter Q3 of 2024


TFX

$222.14

$14.7600 7.12%



Teleflex Incorporated

Teleflex Incorporated stock went up 7.12% during this current quarter q3 of 2024.


Teleflex Incorporated operates with a diversified business model focused on the design, development, manufacturing, and distribution of specialty medical devices. The company offers a wide range of products and solutions across multiple medical fields, including critical care, surgical, and respiratory care. Teleflex*s business model centers around providing innovative, high-quality medical technologies to healthcare professionals globally, aiming to improve patient outcomes and enhance procedural efficiency.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 10,528.103 mill. $ 3,000.133 mill. $ 294.869 mill. 47 mill. 35.67 Y/Y 3.69 %
Market Cap. Revenues TTM Net Income TTM

$ 10,528.103 mill.


$ 3,000.133 mill.


$ 294.869 mill.

Employees Shares Outstanding P/E

14,000


47 mill.


35.67

Revenue Growth Income Growth

MRQ Y/Y 3.69 %


MRQ Y/Y -80.08 %



IQV

$240.445

$13.2750 5.84%
This Quarter Q3 of 2024


IQV

$240.445

$13.2750 5.84%



Iqvia Holdings Inc

Iqvia Holdings Inc stock improved 5.84% during this current quarter q3 of 2024.


IQVIA Holdings Inc is a multinational company that operates in the healthcare industry. Its business model revolves around providing advanced analytics, technology solutions, and clinical research services to help clients make informed decisions, optimize their operations, and accelerate drug development. By leveraging its vast data resources and expertise, IQVIA aims to support healthcare professionals in improving patient outcomes and driving innovation in the industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 44,314.014 mill. $ 15,155.000 mill. $ 1,423.000 mill. 184 mill. 31.08 Y/Y 2.31 %
Market Cap. Revenues TTM Net Income TTM

$ 44,314.014 mill.


$ 15,155.000 mill.


$ 1,423.000 mill.

Employees Shares Outstanding P/E

79,000


184 mill.


31.08

Revenue Growth Income Growth

MRQ Y/Y 2.31 %


MRQ Y/Y 22.22 %



ABBV

$173.345

$8.6850 5.27%
This Quarter Q3 of 2024


ABBV

$173.345

$8.6850 5.27%



Abbvie Inc

Abbvie Inc stock improved 5.27% during this current quarter q3 of 2024.


Abbvie Inc operates primarily as a global biopharmaceutical company. Its business model centers around researching, developing, manufacturing, and commercializing advanced therapies and medications focusing on critical areas like immunology, oncology, neuroscience, virology, and more. By leveraging its expertise and capabilities, Abbvie aims to improve patient outcomes, address unmet medical needs, and provide value to its stakeholders in the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 307,340.685 mill. $ 54,403.000 mill. $ 6,004.000 mill. 1,773 mill. 51.37 Y/Y 0.70 %
Market Cap. Revenues TTM Net Income TTM

$ 307,340.685 mill.


$ 54,403.000 mill.


$ 6,004.000 mill.

Employees Shares Outstanding P/E

50,000


1,773 mill.


51.37

Revenue Growth Income Growth

MRQ Y/Y 0.70 %


MRQ Y/Y 469.29 %



LH

$209.9175

$10.4675 5.25%
This Quarter Q3 of 2024


LH

$209.9175

$10.4675 5.25%



Laboratory Corporation Of America Holdings

Laboratory Corporation Of America Holdings shares increased 5.25% during this current quarter q3 of 2024.


Laboratory Corporation Of America Holdings operates as a leading healthcare diagnostics company. They offer a range of clinical laboratory tests and services to healthcare providers, pharmaceutical companies, and government agencies. Their business model focuses on providing accurate and timely test results, enabling healthcare professionals to diagnose, treat, and monitor patients effectively.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 17,792.264 mill. $ 11,560.300 mill. $ 434.200 mill. 85 mill. 42.40 Y/Y -15.92 %
Market Cap. Revenues TTM Net Income TTM

$ 17,792.264 mill.


$ 11,560.300 mill.


$ 434.200 mill.

Employees Shares Outstanding P/E

75,500


85 mill.


42.40

Revenue Growth Income Growth

MRQ Y/Y -15.92 %


MRQ Y/Y 7.03 %



SYK

$343.74

$16.2900 4.97%
This Quarter Q3 of 2024


SYK

$343.74

$16.2900 4.97%



Stryker Corp

Stryker Corp stock went up 4.97% during this current quarter q3 of 2024.


Stryker Corp*s business model is based on developing and manufacturing a wide range of medical technologies and devices for the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 132,374.274 mill. $ 20,963.000 mill. $ 3,361.000 mill. 385 mill. 39.32 Y/Y 9.73 %
Market Cap. Revenues TTM Net Income TTM

$ 132,374.274 mill.


$ 20,963.000 mill.


$ 3,361.000 mill.

Employees Shares Outstanding P/E

46,000


385 mill.


39.32

Revenue Growth Income Growth

MRQ Y/Y 9.73 %


MRQ Y/Y 33.11 %



JNJ

$152.53

$6.7900 4.66%
This Quarter Q3 of 2024


JNJ

$152.53

$6.7900 4.66%



Johnson and Johnson

Johnson And Johnson shares went up 4.66% during this current quarter q3 of 2024.


Johnson & Johnson operates as a multinational healthcare company with a diversified model. They develop, manufacture, and sell a broad range of pharmaceutical, medical devices, and consumer goods. Their business is focused on improving the health and well-being of people worldwide through innovation, research, and strategic acquisitions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 370,663.153 mill. $ 89,659.000 mill. $ 38,476.000 mill. 2,430 mill. 10.04 Y/Y -13.59 %
Market Cap. Revenues TTM Net Income TTM

$ 370,663.153 mill.


$ 89,659.000 mill.


$ 38,476.000 mill.

Employees Shares Outstanding P/E

141,700


2,430 mill.


10.04

Revenue Growth Income Growth

MRQ Y/Y -13.59 %


MRQ Y/Y - %



CTLT

$58.25

$2.4500 4.39%
This Quarter Q3 of 2024


CTLT

$58.25

$2.4500 4.39%



Catalent Inc

Catalent Inc shares improved 4.39% during this current quarter q3 of 2024.


Catalent Inc*s business model is based on providing advanced delivery technologies and development solutions for pharmaceutical, biotechnology, and consumer health companies. They offer a range of services including drug development, manufacturing, packaging, and supply chain capabilities. Their focus is on helping their clients bring innovative and life-saving products to market efficiently and effectively.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 10,505.804 mill. $ 4,135.000 mill. $ -1,176.000 mill. 180 mill. - Y/Y 3.57 %
Market Cap. Revenues TTM Net Income TTM

$ 10,505.804 mill.


$ 4,135.000 mill.


$ -1,176.000 mill.

Employees Shares Outstanding P/E

19,000


180 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 3.57 %


MRQ Y/Y - %



WAT

$306.57

$12.3400 4.19%
This Quarter Q3 of 2024


WAT

$306.57

$12.3400 4.19%



Waters Corp

Waters Corp shares improved 4.19% during this current quarter q3 of 2024.


Waters Corp is a global scientific company that primarily operates in the field of analytical instrument systems. They specialize in the development, manufacturing, and sale of high-performance liquid chromatography (HPLC), mass spectrometry (MS), and thermal analysis systems for laboratory use. By providing efficient and advanced solutions to customers, Waters Corp aims to assist various industries in their research, development, and quality control processes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 23,098.517 mill. $ - mill. $ 593.794 mill. 75 mill. 39.97 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 23,098.517 mill.


$ - mill.


$ 593.794 mill.

Employees Shares Outstanding P/E

7,800


75 mill.


39.97

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HSIC

$71.015

$1.0450 1.49%
This Quarter Q3 of 2024


HSIC

$71.015

$1.0450 1.49%



Henry Schein Inc

Henry Schein Inc shares increased 1.49% during this current quarter q3 of 2024.


Henry Schein Inc is a global distributor of healthcare products, services, and technology solutions to dental and medical professionals. They operate through a vast network of sales consultants, offering a wide range of products from various manufacturers to meet their customers* needs. Their business model focuses on providing high-quality products, innovative solutions, and superior customer service to enhance patient care and improve practice efficiency.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9,215.587 mill. $ 12,451.000 mill. $ 406.000 mill. 130 mill. 23.92 Y/Y 3.66 %
Market Cap. Revenues TTM Net Income TTM

$ 9,215.587 mill.


$ 12,451.000 mill.


$ 406.000 mill.

Employees Shares Outstanding P/E

21,600


130 mill.


23.92

Revenue Growth Income Growth

MRQ Y/Y 3.66 %


MRQ Y/Y -23.44 %



A

$134.39

$1.9500 1.47%
This Quarter Q3 of 2024


A

$134.39

$1.9500 1.47%



Agilent Technologies inc

Agilent Technologies Inc shares increased 1.47% during this current quarter q3 of 2024.


Agilent Technologies Inc. operates under a business model focused on providing innovative measurement solutions to various industries, including life sciences, diagnostics, and chemical analysis. They generate revenue through the sale of their instruments, software, and consumables, as well as offering services to support these products. Agilent also maintains strong collaborations and partnerships with key players in the industry to further expand their reach and impact.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 39,376.270 mill. $ 6,650.000 mill. $ 1,196.000 mill. 293 mill. 32.92 Y/Y -10.42 %
Market Cap. Revenues TTM Net Income TTM

$ 39,376.270 mill.


$ 6,650.000 mill.


$ 1,196.000 mill.

Employees Shares Outstanding P/E

18,100


293 mill.


32.92

Revenue Growth Income Growth

MRQ Y/Y -10.42 %


MRQ Y/Y -12.50 %



MDT

$79.4

$0.2100 0.27%
This Quarter Q3 of 2024


MDT

$79.4

$0.2100 0.27%



Medtronic Plc

Medtronic Plc shares went up 0.27% during this current quarter q3 of 2024.


Medtronic Plc is a global medical technology company that operates primarily through four business segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. Their business model revolves around designing, manufacturing, and distributing medical devices and therapies for the treatment of a wide range of medical conditions, including cardiovascular diseases, neurological disorders, and diabetes. Medtronic Plc also focuses on collaborating with healthcare providers to improve patient outcomes and reduce healthcare costs through innovative solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 105,751.594 mill. $ 32,364.000 mill. $ 3,705.000 mill. 1,332 mill. 28.83 Y/Y 0.53 %
Market Cap. Revenues TTM Net Income TTM

$ 105,751.594 mill.


$ 32,364.000 mill.


$ 3,705.000 mill.

Employees Shares Outstanding P/E

95,000


1,332 mill.


28.83

Revenue Growth Income Growth

MRQ Y/Y 0.53 %


MRQ Y/Y -44.49 %



MRK

$124.94

$-0.2900 -0.23%
This Quarter Q3 of 2024


MRK

$124.94

$-0.2900 -0.23%



Merck and Co Inc

Merck And Co Inc stock declined -0.23% during this current quarter q3 of 2024.


Merck and Co Inc operates primarily as a research-intensive pharmaceutical company, engaging in the development, manufacturing, and marketing of prescription drugs and vaccines worldwide. The company focuses on discovering innovative solutions to address unmet medical needs across various therapeutic areas, collaborating with academic institutions and conducting clinical trials to evaluate the efficacy and safety of their products. Merck and Co Inc also holds a strong commitment to the well-being of patients and aims to contribute to global healthcare by delivering high-quality, affordable medications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 318,162.717 mill. $ 61,403.000 mill. $ 2,319.000 mill. 2,547 mill. 132.46 Y/Y 8.89 %
Market Cap. Revenues TTM Net Income TTM

$ 318,162.717 mill.


$ 61,403.000 mill.


$ 2,319.000 mill.

Employees Shares Outstanding P/E

68,000


2,547 mill.


132.46

Revenue Growth Income Growth

MRQ Y/Y 8.89 %


MRQ Y/Y 68.74 %



BDX

$231.66

$-1.4900 -0.64%
This Quarter Q3 of 2024


BDX

$231.66

$-1.4900 -0.64%



Becton Dickinson And Company

Becton Dickinson And Company stock declined -0.64% during this current quarter q3 of 2024.


Becton Dickinson and Company is a global medical technology company that manufactures and sells a wide range of medical devices, instruments, and reagents. They operate under a business model centered around delivering innovative healthcare solutions to improve patient outcomes and enhance clinical efficiencies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 67,244.011 mill. $ 19,716.000 mill. $ 1,332.000 mill. 290 mill. 51.06 Y/Y 4.65 %
Market Cap. Revenues TTM Net Income TTM

$ 67,244.011 mill.


$ 19,716.000 mill.


$ 1,332.000 mill.

Employees Shares Outstanding P/E

77,000


290 mill.


51.06

Revenue Growth Income Growth

MRQ Y/Y 4.65 %


MRQ Y/Y 16.49 %



ABT

$103.855

$-1.4150 -1.34%
This Quarter Q3 of 2024


ABT

$103.855

$-1.4150 -1.34%



Abbott Laboratories

Abbott Laboratories shares declined -1.34% during this current quarter q3 of 2024.


Abbott Laboratories operates as a diversified healthcare company with a broad portfolio of products. Their business model is centered around developing and manufacturing various health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. They aim to serve a wide range of healthcare sectors globally by providing innovative solutions that improve the quality of patients* lives.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 181,710.108 mill. $ 40,326.000 mill. $ 5,630.000 mill. 1,750 mill. 32.29 Y/Y 2.23 %
Market Cap. Revenues TTM Net Income TTM

$ 181,710.108 mill.


$ 40,326.000 mill.


$ 5,630.000 mill.

Employees Shares Outstanding P/E

113,000


1,750 mill.


32.29

Revenue Growth Income Growth

MRQ Y/Y 2.23 %


MRQ Y/Y -7.06 %



CRL

$222.605

$-4.9450 -2.17%
This Quarter Q3 of 2024


CRL

$222.605

$-4.9450 -2.17%



Charles River Laboratories International inc

Charles River Laboratories International Inc stock declined -2.17% during this current quarter q3 of 2024.


Charles River Laboratories International Inc is a contract research organization (CRO) that provides essential services and support to the pharmaceutical, biotech, and medical device industries. They offer a wide range of research models, drug discovery and development services, safety assessments, and laboratory animal medicine to assist in the preclinical and clinical stages of drug development.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11,540.288 mill. $ 4,111.596 mill. $ 450.898 mill. 52 mill. 26.18 Y/Y -1.73 %
Market Cap. Revenues TTM Net Income TTM

$ 11,540.288 mill.


$ 4,111.596 mill.


$ 450.898 mill.

Employees Shares Outstanding P/E

20,000


52 mill.


26.18

Revenue Growth Income Growth

MRQ Y/Y -1.73 %


MRQ Y/Y -28.35 %



PDCO

$24.79

$-0.6800 -2.67%
This Quarter Q3 of 2024


PDCO

$24.79

$-0.6800 -2.67%



Patterson Companies Inc

Patterson Companies Inc shares went down -2.67% during this current quarter q3 of 2024.


Patterson Companies Inc*s business model focuses on distributing and selling a wide range of products and solutions to various industries, including dental, animal health, and rehabilitation.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,293.546 mill. $ 6,565.239 mill. $ 193.420 mill. 93 mill. 12.21 Y/Y 0.95 %
Market Cap. Revenues TTM Net Income TTM

$ 2,293.546 mill.


$ 6,565.239 mill.


$ 193.420 mill.

Employees Shares Outstanding P/E

7,000


93 mill.


12.21

Revenue Growth Income Growth

MRQ Y/Y 0.95 %


MRQ Y/Y -11.61 %



QDEL

$35.775

$-2.4850 -6.50%
This Quarter Q3 of 2024


QDEL

$35.775

$-2.4850 -6.50%



Quidelortho Corp

Quidelortho Corp shares went down -6.50% during this current quarter q3 of 2024.


Quidelortho Corp operates on a business model that focuses on manufacturing and selling orthodontic products. They leverage their expertise in the orthodontic industry to design and create quality products that cater to the needs of orthodontists and patients. Their revenue is generated through the sales of these products to orthodontic practices and distribution through strategic partnerships.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,393.348 mill. $ 2,966.200 mill. $ -1,723.100 mill. 67 mill. - Y/Y -17.95 %
Market Cap. Revenues TTM Net Income TTM

$ 2,393.348 mill.


$ 2,966.200 mill.


$ -1,723.100 mill.

Employees Shares Outstanding P/E

-


67 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -17.95 %


MRQ Y/Y - %



ZBH

$110.17

$-9.1600 -7.68%
This Quarter Q3 of 2024


ZBH

$110.17

$-9.1600 -7.68%



Zimmer Biomet Holdings Inc

Zimmer Biomet Holdings Inc stock declined -7.68% during this current quarter q3 of 2024.


Zimmer Biomet Holdings Inc operates as a global leader in musculoskeletal healthcare, providing innovative solutions for joint replacement, sports medicine, spine, dental implants, and other surgical products. The company*s business model centers around designing, manufacturing, and marketing these medical devices and equipment to healthcare professionals worldwide, with a focus on improving patient outcomes and advancing the field of musculoskeletal healthcare.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 23,135.700 mill. $ 7,279.300 mill. $ 475.200 mill. 210 mill. 48.77 Y/Y 5.02 %
Market Cap. Revenues TTM Net Income TTM

$ 23,135.700 mill.


$ 7,279.300 mill.


$ 475.200 mill.

Employees Shares Outstanding P/E

19,500


210 mill.


48.77

Revenue Growth Income Growth

MRQ Y/Y 5.02 %


MRQ Y/Y -16.12 %



BAX

$35.13

$-4.5200 -11.40%
This Quarter Q3 of 2024


BAX

$35.13

$-4.5200 -11.40%



Baxter International Inc

Baxter International Inc stock dropped -11.40% during this current quarter q3 of 2024.


Baxter International Inc is a global healthcare company that specializes in providing a wide range of medical products and services. They operate through various business segments including Pharmaceuticals, Medical Products, and Renal Care, offering solutions for hospitals, clinics, and home-based healthcare settings.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 17,916.300 mill. $ 14,756.000 mill. $ 2,657.000 mill. 510 mill. 6.75 Y/Y -1.56 %
Market Cap. Revenues TTM Net Income TTM

$ 17,916.300 mill.


$ 14,756.000 mill.


$ 2,657.000 mill.

Employees Shares Outstanding P/E

60,000


510 mill.


6.75

Revenue Growth Income Growth

MRQ Y/Y -1.56 %


MRQ Y/Y -13.33 %



BMY

$42.19

$-6.1100 -12.65%
This Quarter Q3 of 2024


BMY

$42.19

$-6.1100 -12.65%



Bristol myers Squibb Company

Bristol Myers Squibb Company shares declined -12.65% during this current quarter q3 of 2024.


Bristol Myers Squibb Company is a pharmaceutical firm that operates on a research and development-driven business model, focused on discovering, developing, and delivering innovative medicines to treat various diseases. The company collaborates with academic institutions, government organizations, and other pharmaceutical companies to advance their portfolio of therapeutics and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 85,318.351 mill. $ 45,534.000 mill. $ -6,135.000 mill. 2,022 mill. - Y/Y 4.66 %
Market Cap. Revenues TTM Net Income TTM

$ 85,318.351 mill.


$ 45,534.000 mill.


$ -6,135.000 mill.

Employees Shares Outstanding P/E

32,200


2,022 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 4.66 %


MRQ Y/Y - %



XRAY

$26.2

$-4.2400 -13.93%
This Quarter Q3 of 2024


XRAY

$26.2

$-4.2400 -13.93%



Dentsply Sirona Inc

Dentsply Sirona Inc shares went down -13.93% during this current quarter q3 of 2024.


Dentsply Sirona Inc is a leading dental solutions provider, offering a comprehensive portfolio of dental products and technologies. Their business model focuses on manufacturing and distributing dental equipment, consumables, and digital dentistry solutions to dental professionals worldwide. By combining innovation, research, and customer-centricity, they strive to empower dental professionals to deliver the best possible patient care.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,462.700 mill. $ 3,906.000 mill. $ -187.000 mill. 209 mill. - Y/Y -3.05 %
Market Cap. Revenues TTM Net Income TTM

$ 5,462.700 mill.


$ 3,906.000 mill.


$ -187.000 mill.

Employees Shares Outstanding P/E

15,000


209 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -3.05 %


MRQ Y/Y - %




 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com